| Autor: |
Sae-Won Han, Yongjun Cha, Agnes Paquet, Weidong Huang, Jodi Weidler, Yolanda Lie, Thomas Sherwood, Michael Bates, Mojgan Haddad, In Hae Park, Do-Youn Oh, Keun Seok Lee, Seock-Ah Im, Yung-Jue Bang, Jungsil Ro, Tae-You Kim |
| Jazyk: |
angličtina |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 7, Iss 7, p e39943 (2012) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0039943 |
| Popis: |
BACKGROUND: Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine. METHODS: Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression were quantified in formalin-fixed paraffin-embedded samples using the VeraTag assays. Patients received lapatinib and capecitabine treatment following trastuzumab failure according to the Lapatinib Expanded Access Program. The association between the protein expression levels and clinical outcomes was analyzed. RESULTS: A total of 52 patients were evaluable. H2T level was significantly higher in responders (median 93.49 in partial response, 47.66 in stable disease, and 17.27 in progressive disease; p = 0.020). Longer time-to-progression (TTP) was observed in patients with high H2T [p = 0.018, median 5.2 months in high (>14.95) vs. 1.8 in low (0.605) vs. 2.2 in low ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
